Is McKesson Corporation (MCK) a risky stock?
As of July 21, 2026, Clavix grades McKesson Corporation (MCK) B- for risk, a composite score of 67 out of 100 on an A+ to F scale, which puts MCK in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind MCK's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how MCK scores on each, as of July 21, 2026.
What's moving MCK's risk right now
Company-specific signals Clavix flags behind MCK's current grade, drawn from recent news and filings as of July 21, 2026.
Headlines covered a dismissed UnitedHealth defamation suit, a UK political editorial, and a China AI newsletter, none tied to McKesson's drug distribution business.
Pieces discussed humanities funding cuts at UK universities and a Colorado farm using solar panels. Neither item relates to McKesson's pharmaceutical operations.
The Guardian published a reflective piece about pre-internet life. No McKesson-related catalysts appeared in the recent news roundup.
What a B- grade means
On the Clavix A+ to F scale, MCK's composite of 67 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell MCK or any security. Grades are risk indicators, not predictions of return. Data may be delayed.